Future of personalized medicine in oncology: a systems biology approach.
The development of cost-effective technologies able to comprehensively assess DNA, RNA, protein, and metabolites in patient tumors has fueled efforts to tailor medical care. Indeed validated molecular tests assessing tumor tissue or patient germline DNA already drive therapeutic decision making. However, many theoretical and regulatory challenges must still be overcome before fully realizing the promise of personalized molecular medicine. The masses of data generated by high-throughput technologies are challenging to manage, visualize, and convert to the knowledge required to improve patient outcomes. Systems biology integrates engineering, physics, and mathematical approaches with biologic and medical insights in an iterative process to visualize the interconnected events within a cell that determine how inputs from the environment and the network rewiring that occurs due to the genomic aberrations acquired by patient tumors determines cellular behavior and patient outcomes. A cross-disciplinary systems biology effort will be necessary to convert the information contained in multidimensional data sets into useful biomarkers that can classify patient tumors by prognosis and response to therapeutic modalities and to identify the drivers of tumor behavior that are optimal targets for therapy. An understanding of the effects of targeted therapeutics on signaling networks and homeostatic regulatory loops will be necessary to prevent inadvertent effects as well as to develop rational combinatorial therapies. Systems biology approaches identifying molecular drivers and biomarkers will lead to the implementation of smaller, shorter, cheaper, and individualized clinical trials that will increase the success rate and hasten the implementation of effective therapies into the clinical armamentarium.
Gonzalez-Angulo
Ana Maria
AM
Department of Breast Medical Oncology, The University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Blvd., Houston, TX 77030-4009, USA. agonzalez@mdanderson.org
Hennessy
Bryan T J
BT
Mills
Gordon B
GB
D000971:Antineoplastic Combined Chemotherapy Protocols; D014408:Biomarkers, Tumor / Q000235:genetics; D002986:Clinical Trials as Topic; D016503:Drug Delivery Systems; D005260:Female; D005544:Forecasting; D020022:Genetic Predisposition to Disease / Q000453:epidemiology; D006801:Humans; D008297:Male; D009369:Neoplasms / Q000175:diagnosis / Q000188:drug therapy* / Q000235:genetics*; D010597:Pharmacogenetics; D057285:Precision Medicine / Q000379:methods / Q000639:trends*; D011379:Prognosis; D040901:Proteomics; D049490:Systems Biology / Q000379:methods / Q000639:trends*; D016896:Treatment Outcome
D014408:Biomarkers, Tumor
Int J Cancer. 1995 Aug 22;64(4):280-5
7657393
Cell. 2003 Nov 26;115(5):523-35
14651845
J Clin Oncol. 2009 Mar 1;27(7):1130-6
19124802
Nat Genet. 2007 Jan;39(1):75-9
17143282
Cancer Cell. 2007 Oct;12(4):395-402
17936563
Cancer Res. 2009 Jan 1;69(1):143-50
19117997
Nat Genet. 2005 Jan;37(1):48-55
15608639
Nat Med. 2004 Nov;10(11):1251-6
15502842
Cell Cycle. 2009 Jun 15;8(12):1872-6
19440052
Nature. 2008 Oct 23;455(7216):1061-8
18772890
Cancer Cell. 2006 Dec;10(6):529-41
17157792
Mol Cancer Ther. 2009 Aug;8(8):2079-85
19671763
N Engl J Med. 2009 Feb 19;360(8):790-800
19228622
Clin Cancer Res. 1998 Dec;4(12):2925-9
9865902
Expert Rev Mol Diagn. 2009 Oct;9(7):651-7
19817550
Brief Funct Genomic Proteomic. 2002 Oct;1(3):305-15
15239896
Adv Biochem Eng Biotechnol. 2002;77:57-74
12227737
Genes Chromosomes Cancer. 2006 Nov;45(11):1033-40
16897746
Nature. 2006 Jan 19;439(7074):353-7
16273092
J Clin Oncol. 2005 Mar 20;23(9):2020-7
15774793
J Natl Cancer Inst. 1991 Jun 5;83(11):757-66
2041050
Clin Cancer Res. 2007 May 15;13(10):2890-6
17504988
J Clin Oncol. 2006 Aug 10;24(23):3726-34
16720680
Ann N Y Acad Sci. 2008 Sep;1138:136-45
18837894
Nat Rev Drug Discov. 2005 Dec;4(12):988-1004
16341064
Nucleic Acids Res. 2008 Nov;36(20):6535-47
18927117
Proteomics. 2003 Nov;3(11):2085-90
14595806
Proc Natl Acad Sci U S A. 2002 Dec 10;99(25):16156-61
12461184
Science. 1989 May 12;244(4905):707-12
2470152
Proc Natl Acad Sci U S A. 2003 Nov 25;100(24):14229-34
14623978
Nat Methods. 2007 Oct;4(10):855-60
17767164
Clin Cancer Res. 2009 Jan 15;15(2):417-9
19147744
APMIS. 2008 Jul-Aug;116(7-8):629-37
18834407
Cancer Res. 2008 Aug 1;68(15):6084-91
18676830
Nat Genet. 2007 Mar;39(3):347-51
17293865
N Engl J Med. 2005 Feb 24;352(8):786-92
15728811
Proc Natl Acad Sci U S A. 2005 Sep 27;102(39):14004-9
16172393
Oncogene. 2007 Oct 25;26(49):6997-7005
17486065
Proc Natl Acad Sci U S A. 2008 Oct 21;105(42):16224-9
18852474
Nat Med. 2008 Dec;14(12):1351-6
19029981
Cancer Res. 2006 Feb 1;66(3):1500-8
16452206
Cancer Res. 2009 May 15;69(10):4116-24
19435916
Proteomics. 2003 Nov;3(11):2142-6
14595813
J Clin Oncol. 2005 Feb 20;23(6):1169-77
15718313
Lab Invest. 2004 Feb;84(2):235-44
14767488